Paxil study 329 results - source GSK

[Guest guest]

[PDF]

study 329 File Format: PDF/Adobe Acrobat - Quick ViewImipramine in Adolescents with Unipolar Major Depression - Acute Phase. (29060/ 329). Investigators and Centers. Investigators from 10 centers in the United ...www.gsk.com/media/paroxetine/depression_329.pdf

Objectives

The primary objective was to compare the efficacy and safety of imipramine and

paroxetine to placebo in the treatment of adolescents with unipolar major

depression.

The secondary objectives were as follows: to identify predictors of treatment

outcomes across clinical subtypes of major depressive disorder; to provide

information on the safety profile of paroxetine and imipramine when these agents

were given for an extended period of time; to estimate the rate of relapse among

imipramine, paroxetine and placebo responders who were maintained on

treatment.

This report presents the results from the 8 week acute phase. Findings from the

continuation phase, which include long term safety and the analysis of relapse,

will be reported separately.

> >> >> > Paxil Study 329: Paroxetine vs Imipramine vs Placebo in Adolescents> >> > by Jon Jureidini> >> > This page was published earlier in 2008 in our old website at:> > http> >> >>

[Guest guest]

[PDF]

study 329 File Format: PDF/Adobe Acrobat - Quick ViewImipramine in Adolescents with Unipolar Major Depression - Acute Phase. (29060/ 329). Investigators and Centers. Investigators from 10 centers in the United ...www.gsk.com/media/paroxetine/depression_329.pdf

Objectives

The primary objective was to compare the efficacy and safety of imipramine and

paroxetine to placebo in the treatment of adolescents with unipolar major

depression.

The secondary objectives were as follows: to identify predictors of treatment

outcomes across clinical subtypes of major depressive disorder; to provide

information on the safety profile of paroxetine and imipramine when these agents

were given for an extended period of time; to estimate the rate of relapse among

imipramine, paroxetine and placebo responders who were maintained on

treatment.

This report presents the results from the 8 week acute phase. Findings from the

continuation phase, which include long term safety and the analysis of relapse,

will be reported separately.

> >> >> > Paxil Study 329: Paroxetine vs Imipramine vs Placebo in Adolescents> >> > by Jon Jureidini> >> > This page was published earlier in 2008 in our old website at:> > http> >> >>

[Guest guest]

[PDF]

study 329 File Format: PDF/Adobe Acrobat - Quick ViewImipramine in Adolescents with Unipolar Major Depression - Acute Phase. (29060/ 329). Investigators and Centers. Investigators from 10 centers in the United ...www.gsk.com/media/paroxetine/depression_329.pdf

Objectives

The primary objective was to compare the efficacy and safety of imipramine and

paroxetine to placebo in the treatment of adolescents with unipolar major

depression.

The secondary objectives were as follows: to identify predictors of treatment

outcomes across clinical subtypes of major depressive disorder; to provide

information on the safety profile of paroxetine and imipramine when these agents

were given for an extended period of time; to estimate the rate of relapse among

imipramine, paroxetine and placebo responders who were maintained on

treatment.

This report presents the results from the 8 week acute phase. Findings from the

continuation phase, which include long term safety and the analysis of relapse,

will be reported separately.

> >> >> > Paxil Study 329: Paroxetine vs Imipramine vs Placebo in Adolescents> >> > by Jon Jureidini> >> > This page was published earlier in 2008 in our old website at:> > http> >> >>

[Guest guest]

[PDF]

study 329 File Format: PDF/Adobe Acrobat - Quick ViewImipramine in Adolescents with Unipolar Major Depression - Acute Phase. (29060/ 329). Investigators and Centers. Investigators from 10 centers in the United ...www.gsk.com/media/paroxetine/depression_329.pdf

Objectives

The primary objective was to compare the efficacy and safety of imipramine and

paroxetine to placebo in the treatment of adolescents with unipolar major

depression.

The secondary objectives were as follows: to identify predictors of treatment

outcomes across clinical subtypes of major depressive disorder; to provide

information on the safety profile of paroxetine and imipramine when these agents

were given for an extended period of time; to estimate the rate of relapse among

imipramine, paroxetine and placebo responders who were maintained on

treatment.

This report presents the results from the 8 week acute phase. Findings from the

continuation phase, which include long term safety and the analysis of relapse,

will be reported separately.

> >> >> > Paxil Study 329: Paroxetine vs Imipramine vs Placebo in Adolescents> >> > by Jon Jureidini> >> > This page was published earlier in 2008 in our old website at:> > http> >> >>